Pfizer $195M Deal for Encysive Called a 'Good Deal' For Both Feb. 21, 2008 By Catherine Hollingsworth No Comments
Pfizer $195M Deal for Encysive Called a 'Good Deal' For Both Feb. 21, 2008 By Catherine Hollingsworth No Comments
Biogen Idec, Cardiokine Begin Phase III Study of Lixivaptan Feb. 15, 2008 By Catherine Hollingsworth No Comments
Biogen Idec, Cardiokine Begin Phase III Study of Lixivaptan Feb. 15, 2008 By Catherine Hollingsworth No Comments
Vertex Offerings Expected to Raise up to $405.8M Feb. 14, 2008 By Catherine Hollingsworth No Comments
Vertex Offerings Expected to Raise up to $405.8M Feb. 14, 2008 By Catherine Hollingsworth No Comments
